UNH Research Note — Recovery Still Has Conditions
UnitedHealth has two quarters of medical-cost improvement, but the recovery remains narrow and legal risk is unresolved.
CAMS Free Update
Market Structure: Healthcare Leads, Event Risk Builds — August 10, 2026
Healthcare leads the three-month tape while concentrated technology gains and this earnings-heavy calendar raise the bar for follow-through.
NVDA Research Note — The Proof Is August 26
NVIDIA retains exceptional growth and margins, while a fuller valuation makes the August 26 report the next decisive evidence point.
VRT Research Note — Backlog Meets the Conversion Test
Orders and backlog surged, but the July revenue shortfall leaves conversion as the central evidence test.
Market Structure: Risk-On Tape, Neutral Macro — August 10, 2026
Broad market participation supports the advance, while a contracting July payroll reading and a 4.66% ten-year yield temper the broader macro case.
BIVI Research Note — Evidence Before Optimism
BioVie’s subgroup signal does not resolve the missing registered endpoint or the scale of pending dilution.
VICI Research Note — The Tenant Concentration Test
VICI looks inexpensive on AFFO and yield, but Caesars lease talks and two-tenant concentration explain why the discount persists.
WULF Research Note — Backlog Meets Dilution
WULF’s HPC mix shifted sharply, but declining revenue, negative adjusted EBITDA and a rising share count keep financing quality central.
TSM Research Note — Capacity Meets the Macro Test
TSMC’s margins and revenue remain strong today, while macro risk and capital conversion define the next test for the foundry’s premium valuation.
JQC Research Note — Coverage Has to Catch Up
JQC’s 11.01% discount is clear, while 75% historical distribution coverage leaves the March payout reset awaiting September confirmation from Nuveen.